What is GeneCapture?
GeneCapture operates at the intersection of biotechnology and point-of-care diagnostics, having engineered the CAPTURE Platform. This portable, high-efficiency solution is designed to address the critical global challenge of antimicrobial resistance by providing rapid pathogen identification and antibiotic susceptibility testing. Unlike traditional laboratory-dependent workflows that often require extensive infrastructure and time-consuming incubation periods, the CAPTURE Platform delivers actionable clinical data within a three-hour window. Its ability to function in diverse, resource-constrained environments—ranging from remote clinical settings and agricultural facilities to tactical field operations—positions GeneCapture as a pivotal player in the future of decentralized healthcare delivery. By eliminating the need for cold-chain logistics and specialized laboratory equipment, the company is effectively democratizing access to high-fidelity diagnostic insights.
How much funding has GeneCapture raised?
GeneCapture has raised a total of $85K across 2 funding rounds:
Debt
$35K
Debt
$50K
Debt (2021): $35K with participation from PPP
Debt (2026): $50K, investors not publicly disclosed
Key Investors in GeneCapture
PPP
Public-Private Partnership
Undisclosed Investor
A strategic participant in the recent funding round, providing essential capital to drive the commercialization of diagnostic innovations.
What's next for GeneCapture?
With the infusion of this latest capital, GeneCapture is expected to transition from its current development phase into a broader commercialization strategy. The firm will likely prioritize the scaling of its manufacturing capabilities to meet anticipated demand across global health sectors. Furthermore, the strategic roadmap includes expanding the diagnostic library of the CAPTURE Platform to encompass a wider array of infectious agents. As the company navigates this growth phase, the focus will remain on securing regulatory milestones and establishing partnerships with healthcare providers to integrate its technology into standard clinical protocols. This expansion is critical for addressing the urgent need for rapid, accurate, and actionable diagnostic tools in the ongoing fight against evolving pathogen threats.
See full GeneCapture company page
